These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32229193)

  • 1. Evaluation of the anti-cervical cancer effect of a prodrug ：CBZ-AAN-DOX with hypoxic cell culture and tumor-bearing zebrafish models.
    Chen HC; Rui W; You SY; Liu XW; Huang J; Chen HY
    Exp Cell Res; 2020 Jun; 391(1):111980. PubMed ID: 32229193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Evaluation of a CBZ-AAN-Dox Prodrug and its in vitro Effects on SiHa Cervical Cancer Cells Under Hypoxic Conditions.
    Chen H; Liu X; Clayman ES; Shao F; Xiao M; Tian X; Fu W; Zhang C; Ruan B; Zhou P; Liu Z; Wang Y; Rui W
    Chem Biol Drug Des; 2015 Oct; 86(4):589-98. PubMed ID: 25619622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
    van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM
    Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain.
    Stern L; Perry R; Ofek P; Many A; Shabat D; Satchi-Fainaro R
    Bioconjug Chem; 2009 Mar; 20(3):500-10. PubMed ID: 19196156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms.
    Wu W; Luo Y; Sun C; Liu Y; Kuo P; Varga J; Xiang R; Reisfeld R; Janda KD; Edgington TS; Liu C
    Cancer Res; 2006 Jan; 66(2):970-80. PubMed ID: 16424032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
    Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
    Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
    Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
    FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective ablation of tumor-associated macrophages suppresses metastasis and angiogenesis.
    Lin Y; Wei C; Liu Y; Qiu Y; Liu C; Guo F
    Cancer Sci; 2013 Sep; 104(9):1217-25. PubMed ID: 23691974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
    Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G
    Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Legumain correlates with neuroblastoma differentiation and can be used in prodrug design.
    Zhang M; Jiang Z; Chen S; Wu Z; Chen K; Wu Y
    Chem Biol Drug Des; 2018 Feb; 91(2):534-544. PubMed ID: 28994241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
    Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
    Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of a novel legumain-cleavable colchicine prodrug with cell-specific toxicity.
    Smith RL; Åstrand OA; Nguyen LM; Elvestrand T; Hagelin G; Solberg R; Johansen HT; Rongved P
    Bioorg Med Chem; 2014 Jul; 22(13):3309-15. PubMed ID: 24842619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
    Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
    J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acid-activatable prodrug nanogels for efficient intracellular doxorubicin release.
    Zhan F; Chen W; Wang Z; Lu W; Cheng R; Deng C; Meng F; Liu H; Zhong Z
    Biomacromolecules; 2011 Oct; 12(10):3612-20. PubMed ID: 21905663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The synthetic flavonoid WYC02-9 inhibits cervical cancer cell migration/invasion and angiogenesis via MAPK14 signaling.
    Chen YJ; Cheng YJ; Hung AC; Wu YC; Hou MF; Tyan YC; Yuan SS
    Gynecol Oncol; 2013 Dec; 131(3):734-43. PubMed ID: 24145114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lectin-Mediated pH-Sensitive Doxorubicin Prodrug for Pre-Targeted Chemotherapy of Colorectal Cancer with Enhanced Efficacy and Reduced Side Effects.
    Yao M; Ma X; Zhang X; Shi L; Liu T; Liang X; Zhao H; Li X; Li L; Gao H; Jia B; Wang F
    Theranostics; 2019; 9(3):747-760. PubMed ID: 30809306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiourea Modified Doxorubicin: A Perspective pH-Sensitive Prodrug.
    Krasnovskaya OO; Malinnikov VM; Dashkova NS; Gerasimov VM; Grishina IV; Kireev II; Lavrushkina SV; Panchenko PA; Zakharko MA; Ignatov PA; Fedorova OA; Jonusauskas G; Skvortsov DA; Kovalev SS; Beloglazkina EK; Zyk NV; Majouga AG
    Bioconjug Chem; 2019 Mar; 30(3):741-750. PubMed ID: 30726065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
    Chen JM; Bai JY; Yang KX
    IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral expression of mature human neutrophil peptide-1 potentiates the therapeutic effect of doxorubicin in a mouse 4T1 breast cancer model.
    Li D; Qin Q; Wang XY; Shi HS; Luo M; Guo FC; Wang W; Wang YS
    Oncol Rep; 2014 Mar; 31(3):1287-95. PubMed ID: 24378474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.